Tue, Apr 29, 8:11 PM (19 days ago)
**NeoGenomics, Inc. (NEO) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** $168.0 million (up 7.5% YoY) - **Gross Profit:** $73.2 million (up 11.9% YoY) - **Gross Margin:** 43.6% (up 1.7% YoY) - **Net Loss:** $25.9 million (down 4.2% YoY) - **Cash and Cash Equivalents:** $346.2 million (down 5.7% YoY) **Key Metrics:** - **Operating Expenses:** $101.1 million (up 5.3% YoY) - **General and Administrative:** $68.2 million (up 3.7% YoY) - **Research and Development:** $10.2 million (up 33.6% YoY) - **Sales and Marketing:** $22.7 million (up 12.2% YoY) - **Interest Income:** $3.7 million (down 23.0% YoY) - **Interest Expense:** $1.6 million (down 4.0% YoY) **Cash Flow:** - **Operating Cash Flow:** -$25.3 million (improved by $0.6 million YoY) - **Investing Cash Flow:** $3.6 million (down $10.9 million YoY) - **Financing Cash Flow:** $0.9 million (up $0.1 million YoY) **Earnings Changes:** - **Basic EPS:** -$0.20 (improved by $0.01 YoY) - **Diluted EPS:** -$0.20 (improved by $0.01 YoY) **Trends and Uncertainties:** - **Revenue Growth:** Driven by increased test volume and strategic reimbursement initiatives. - **Operational Efficiency:** Focus on improving gross margin and operational efficiency. - **Innovation:** Continued investment in research and development for new tests and technologies. - **Legal and Regulatory:** Ongoing legal proceedings and regulatory uncertainties. **Future Operations Impact:** - **Capital Expenditures:** Forecasted at $30.0-$35.0 million for 2025. - **Liquidity:** Sufficient cash and marketable securities to fund near-term capital and operating needs. - **Strategic Focus:** Emphasis on sustainable growth, innovation, and value creation. **Notable Events:** - **Acquisition:** Completed acquisition of Pathline, LLC. - **Segment Simplification:** Consolidated Clinical Services and Advanced Diagnostics into a single segment. **Risk Factors:** - **Market Risks:** Exposure to interest rate and foreign currency exchange rate fluctuations. - **Operational Risks:** Dependence on key personnel, regulatory changes, and competitive pressures. - **Economic Risks:** Potential impacts from global economic conditions and geopolitical tensions. **Conclusion:** NeoGenomics continues to focus on growth through innovation and operational efficiency. The company's strategic initiatives and financial performance indicate a positive outlook, despite ongoing challenges and uncertainties.